Kyverna Reports Durable One-Year SPS and gMG Data; BLA Filing on Track for Q4 2026
KYTX sits 33% above its 52-week low of $5.3.
Summary
Kyverna reported positive one-year durability data from its registrational KYSA-8 trial in stiff person syndrome and longer-term follow-up from KYSA-6 in generalized myasthenia gravis, with a rolling BLA submission on track for Q4 2026.
Key Events · Product Development and Regulatory · KYTX
-
One-Year SPS Data Show Durable Benefit
KYSA-8 12-month follow-up (n=26) showed 49% median T25FW improvement, 95% of responders sustained benefit, 67% of walking-aid patients no longer require assistance, and 92% remained free of chronic immunotherapies.
-
gMG Longer-Term Follow-Up Positive
KYSA-6 Phase 2 data (n=7) showed 100% achieved clinically meaningful improvement at 24 weeks, 57% maintained minimal symptom expression, and 86% remained off immunosuppressants at last follow-up.
-
BLA Submission on Track for Q4 2026
Kyverna intends to include the one-year SPS data in its rolling Biologics License Application, with completion expected in Q4 2026.
-
Phase 3 gMG Enrollment Timeline
Enrollment in the Phase 3 portion of KYSA-6 is expected to be completed by mid-2027.
Analysis · KYTX · Life Sciences
Kyverna's one-year KYSA-8 data in stiff person syndrome show durable, statistically significant improvements in mobility and disability, with 95% of responders sustaining benefit and 92% of patients off chronic immunotherapies. The longer-term gMG follow-up confirms deep, durable responses with a clean safety profile. These results directly support a rolling BLA submission expected to complete in Q4 2026, positioning miv-cel to become the first approved therapy for SPS and the first approved CAR T-cell therapy for autoimmune disease. The data meaningfully de-risk the regulatory path and strengthen the commercial thesis for a lead asset in a market with no approved treatments.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 50.2% of the 203 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYTX was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $437.2M. The 52-week trading range was $5.30 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.